WASHINGTON, Dec. 18, 2025 /PRNewswire/ -- The Trump administration's decision to reschedule cannabis to Schedule III marks the most significant shift in federal cannabis policy in decades. While the ...

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new ...

The UNG women's soccer team has earned the Peach Belt Conference regular-season title for the second time in three years, pulling off the feat with a perfect 10-0 PBC record. Lilyana Hernandez (14) ...

A gamer’s preference for their keyboard switches is a personal affair. You’re almost always guaranteed to start a debate if you ask a room full of gamers which they’d prefer: linear or clicky switches ...

BERLIN — A novel investigational ileal bile acid transporter (IBAT) inhibitor, linerixibat, significantly and rapidly reduced cholestatic pruritus in patients with primary biliary cholangitis (PBC), ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of two per 100,000 people per year and an estimated prevalence of 15 per ...

A line of Nippon Pulse’s linear shaft motors that features analog Hall effect sensors to enable closed-loop positioning without a linear encoder. Linear motors can be described as uncurled 3-phase ...

While the path for any drug to go from lab research to commercialization takes years, Intercept Pharmaceuticals now stands as another example that a product’s market exit can also be long and winding.

Please provide your email address to receive an email when new articles are posted on . Intercept has voluntarily withdrawn its lone product, Ocaliva, from U.S. market for primary biliary cholangitis.

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the autoimmune disease are anti-mitochondrial antibodies (AMA), present in approximately ...